Clinical Trial Update: Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial evaluating a pharmacogenetic approach to tailoring anti-platelet therapy for patients with ST-segment elevation myocardial inf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-segment Elevation Myocardial Infarction

Snippet

Sponsor: Ottawa Heart Institute Research Corporation | Conditions: STEMI | Phase 2, Phase 3 | Status: COMPLETED